Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 20 May 2009, doi:10.1136/bmj.b1979
Cite this as: BMJ 2009;338:b1979
| The first 150 words of the full text of this article appear below. |
Siegel is surprised that we concluded that nicotine replacement therapy was effective and cannot think of other interventions that would be regarded as effective with such a high failure rate.1 He chooses a secondary outcome from our review to make his point, but as it excludes 76% of all the people who stopped smoking for a long time, this is not an accurate measure of the impact of the programme. Overall, offering up to one year of treatment with nicotine replacement therapy helped 6.75%–3.28%=3.47%, or 1 in 29 users sustain long term abstinence. About half will become lifetime abstainers, about half of whom will be prevented from premature death,2 which gives a number needed to treat (NNT) for prevention of premature death of about 120.
This NNT compares favourably with other preventive interventions. Five years of treatment with statins in those at risk of cardiovascular disease gives an NNT of
Paul Aveyard, senior lecturer1, David Moore, senior reviewer1, Martin Connock, systematic reviewer1, Dechao Wang, systematic reviewer1, Anne Fry-Smith, information specialist1, Pelham Barton, senior lecturer1
1 School of Health and Population Sciences, University of Birmingham, Birmingham B15 2TT
p.n.aveyard@bham.ac.uk